An anti-XDR-TB drug including a compound having a structure expressed by Structural Formula (1) below an anti-MDR-TB drug including a compound having a structure expressed by Structural Formula (1) below and a combination anti-tuberculosis drug including a drug containing a compound having a structure expressed by Structural Formula (1) below, and at least one anti-tuberculosis drug selected from an anti-tuberculosis drug containing rifampicin (RFP) and an anti-tuberculosis drug containing isonicotinic acid hydrazide (INH).